Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $105

Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

DNTH

0.00

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ: DNTH) with a Outperform and raises the price target from $103 to $105.